Prolonged Strait of Hormuz standoff will close in on America's generic drug prescriptions

The ongoing tensions in the Strait of Hormuz pose a significant risk to US generic drug supplies since half of these medications are manufactured in India and rely on this vital maritime route. With the threat of supply chain disruptions, US pharmaceutical companies have begun to prepare for potential shortages. Many stockpiles of prescriptions are already limited, heightening consumers' concerns regarding access to essential medications. The situation not only affects healthcare but could also lead to cost increases in the pharmaceutical sector. Investors and traders in related stocks should monitor the developments closely as the standoff continues.